Amoeba SA (ALMIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amoeba SA (ALMIB) has a cash flow conversion efficiency ratio of 0.187x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.67 Million ≈ $-3.12 Million USD) by net assets (€-14.27 Million ≈ $-16.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amoeba SA - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Amoeba SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Amoeba SA (ALMIB) financial obligations for a breakdown of total debt and financial obligations.
Amoeba SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amoeba SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ferronordic AB (publ)
ST:FNM
|
-0.029x |
|
Northwest Copper Corp
V:NWST
|
-0.017x |
|
Shanghai Yaohua Pilkington Glass Group Co Ltd B
SHG:900918
|
0.039x |
|
Future Health Esg Corp
NASDAQ:FHLT
|
0.653x |
|
VELA TECHNOL.PLC LS-0001
F:IBNN
|
N/A |
|
Redtone International Bhd
KLSE:0032
|
-0.013x |
|
Everest Industries Limited
NSE:EVERESTIND
|
-0.029x |
|
Kukje Pharma Co Ltd
KO:002720
|
0.052x |
Annual Cash Flow Conversion Efficiency for Amoeba SA (2012–2024)
The table below shows the annual cash flow conversion efficiency of Amoeba SA from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Amoeba SA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-10.41 Million ≈ $-12.17 Million |
€-4.22 Million ≈ $-4.93 Million |
0.405x | -75.44% |
| 2023-12-31 | €-3.94 Million ≈ $-4.61 Million |
€-6.50 Million ≈ $-7.60 Million |
1.649x | +349.19% |
| 2022-12-31 | €8.16 Million ≈ $9.54 Million |
€-5.40 Million ≈ $-6.32 Million |
-0.662x | +97.77% |
| 2021-12-31 | €198.68K ≈ $232.28K |
€-5.90 Million ≈ $-6.90 Million |
-29.704x | -1727.93% |
| 2020-12-31 | €2.00 Million ≈ $2.34 Million |
€-3.25 Million ≈ $-3.80 Million |
-1.625x | -89.00% |
| 2019-12-31 | €4.23 Million ≈ $4.94 Million |
€-3.64 Million ≈ $-4.25 Million |
-0.860x | +12.73% |
| 2018-12-31 | €5.41K ≈ $6.33K |
€-5.33K ≈ $-6.23K |
-0.985x | -142.87% |
| 2017-12-31 | €12.52K ≈ $14.64K |
€-5.08K ≈ $-5.94K |
-0.406x | -32.43% |
| 2016-12-31 | €18.63K ≈ $21.78K |
€-5.71K ≈ $-6.67K |
-0.306x | +22.04% |
| 2015-12-31 | €10.60K ≈ $12.39K |
€-4.16K ≈ $-4.87K |
-0.393x | +7.81% |
| 2014-12-31 | €2.80 Million ≈ $3.27 Million |
€-1.19 Million ≈ $-1.39 Million |
-0.426x | -136.98% |
| 2013-12-31 | €433.99K ≈ $507.38K |
€500.21K ≈ $584.79K |
1.153x | +771.59% |
| 2012-12-31 | €947.20K ≈ $1.11 Million |
€-162.56K ≈ $-190.04K |
-0.172x | -- |
About Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more